Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1459528 | 0.87 | RAB9A (0.58) | RAB9APOLBALDH1A1MAPTNPC1 | |
| SCHEMBL1745412 | 0.87 | RAB9A (0.71) | RAB9APOLBALDH1A1MAPTNPC1 | |
| SCHEMBL13465148 | 0.86 | TCF4 (0.63) | RAB9APOLBALDH1A1MAPTNPC1 | |
| SCHEMBL5928751 | 0.84 | RAB9A (0.74) | RAB9APOLBALDH1A1MAPTNPC1 | |
| SCHEMBL5928165 | 0.84 | TCF4 (0.64) | RAB9APOLBALDH1A1MAPTNPC1 | |
| SCHEMBL9560810 | 0.84 | MEN1 (0.57) | RAB9APOLBALDH1A1MAPTNPC1 | |
| SCHEMBL13465390 | 0.84 | RAB9A (0.55) | RAB9APOLBALDH1A1MAPTNPC1 | |
| SCHEMBL27928486 | 0.84 | ROCK1 (0.58) | RAB9APOLBALDH1A1MAPTNPC1 | |
| SCHEMBL22453217 | 0.84 | RAB9A (0.59) | RAB9APOLBALDH1A1MAPTNPC1 | |
| SCHEMBL13280274 | 0.82 | AKR1C3 (0.65) | RAB9APOLBMAPTNPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020190774-A1 | NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS | THE GENERAL HOSPITAL CORPORATION (US) | 2020-09-24 | — | — | WO | disclosed |
| US-10071953-B2 | Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-09-11 | — | — | US | disclosed |
| US-20160159731-A1 | Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof | UNIV PENNSYLVANIA (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159731-A1 | Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof | UNIV PENNSYLVANIA (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159731-A1 | Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof | UNIV PENNSYLVANIA (US) | 2016-06-09 | — | — | US | disclosed |
| US-9271961-B2 | Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271961-B2 | Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271961-B2 | Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-03-01 | — | — | US | disclosed |
| US-20140107085-A1 | Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107085-A1 | Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107085-A1 | Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-04-17 | — | — | US | disclosed |
| EP-2594554-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-05-09 | — | — | US | disclosed |
| WO-2012142208-A1 | BIFUNCTIONAL AKR1C3 INHIBITORS/ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071953-B2 | Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof | AR, AKR1C3, AKR1C2 | RAB9A 4786/4885POLB 1398/4885ALDH1A1 230/4885 |
| US-20140107085-A1 | Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof | AR, AKR1C3, AKR1C2 | RAB9A 4786/4885POLB 1398/4885ALDH1A1 230/4885 |
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | MC2R, NR3C2, REN | RAB9A 1250/4885POLB 4291/4885ALDH1A1 1151/4885 |
| US-20160159731-A1 | Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof | AR, AKR1C3, AKR1C2 | RAB9A 4786/4885POLB 1398/4885ALDH1A1 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.